JANX Stock Risk & Deep Value Analysis
Janux Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About JANX Stock
We analyzed Janux Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran JANX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
JANX Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
High
Competitive
High
Execution
Medium
Regulatory
High
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial data from JANX007, 008, 009
- 📅
Increased competitive pressure in T-cell engager space further impacting market potential
- 📅
Regulatory delays or setbacks in drug development pathways
- 📅
Higher-than-expected cash burn leading to future equity raises
Unlock JANX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Janux Therapeutics Inc (JANX) Do?
Market Cap
$855.29M
Sector
Healthcare
Industry
Biotechnology
Employees
103
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Visit Janux Therapeutics Inc WebsiteInvestment Thesis
Janux Therapeutics presents a high-upside, high-risk opportunity driven by its innovative TRACTr platform and a deep pipeline targeting significant unmet needs in oncology and autoimmune diseases. The strong balance sheet, validated by a major BMS partnership, provides a solid foundation for upcoming binary clinical data catalysts throughout 2026 that could unlock substantial value, despite recent competitive headwinds for its JANX007 program.
Is JANX Stock Undervalued?
Unlock the full AI analysis for JANX
Get the complete DVR score, risk analysis, and more
JANX Price Targets & Strategy
12-Month Target
$60.00
Bull Case
$100.00
Bear Case
$15.00
Valuation Basis
Based on a discounted sum-of-the-parts valuation assuming successful clinical advancement of lead assets and a 2x peak sales multiple for one key program, projected 3-5 years out.
Entry Strategy
Dollar-cost average on dips, particularly around the $12-$14 range, which represents recent trading levels; accumulation prior to key clinical data readouts.
Exit Strategy
Consider taking partial profits after significant positive clinical trial readouts or major partnership announcements; implement a stop-loss at $10.00 to manage downside risk.
Portfolio Allocation
7-10% for aggressive risk tolerance, 3-5% for moderate risk tolerance given the binary nature of biotech investments.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is JANX Financially Healthy?
Valuation
P/E Ratio
-7.68
Price/Book
1.28
Price/Sales
141.29
Profitability
Return on Equity
-12.82%
EPS
$-1.83
Balance Sheet
Total Debt
$22.19M
Cash & Equivalents
$996.01M
Cash Flow
Operating Cash Flow
-$50.00M
Free Cash Flow
-$50.00M
EBITDA
-$142.80M
Other
Beta (Volatility)
2.88
Does JANX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability hinges on successful clinical validation of its proprietary platforms and lead drug candidates. If Janux can bring novel, differentiated therapeutics to market, its IP and platform technology will create significant barriers to entry.
Moat Erosion Risks
- •Failure of clinical trials for lead drug candidates
- •Emergence of superior competing technologies or clinical assets
- •Challenges to its intellectual property (IP) portfolio
JANX Competitive Moat Analysis
Sign up to see competitive advantages
JANX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish/Speculative, typical for early-stage biotechs with pipeline catalysts.
Institutional Sentiment
Positive, with 75.39% institutional ownership, but tempered by recent analyst price target cuts due to competitive concerns.
Insider Activity (Form 4)
CEO David Alan Campbell sold 8,072 shares at an unspecified price on 2026-01-02. Total insider sales of 19,033 shares valued at $261,323 in the last 90 days. No insider buys reported.
Options Flow
Normal options activity; no specific unusual options activity reported in real-time intelligence.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (Q1 2026)
Surprise Probability
High
Historical Earnings Pattern
Early-stage biotech earnings reports often trigger volatility based more on pipeline updates and cash runway details than traditional revenue/EPS beats/misses, as overall revenue is negligible.
Key Metrics to Watch
Competitive Position
Top Competitor
CytomX Therapeutics (mentioned for similar negative EV profile, indicating early-stage biotech characteristics). Key emerging competitors in PSMA TCE space (e.g., specific prostate cancer entrants).
Market Share Trend
Too early to establish market share, but facing competitive threats to a key asset (JANX007) from emerging players.
Valuation vs Peers
Trading with a negative Enterprise Value (cash exceeds market cap), suggesting significant undervaluation relative to its cash position, similar to some other early-stage clinical biotechs, but still subject to pipeline risk.
Competitive Advantages
- •Proprietary TRACTr, TRACIr, and ARM platforms for differentiated therapeutics
- •Strategic collaboration with Bristol Myers Squibb (significant validation and funding)
- •Diversified pipeline across oncology and autoimmune diseases
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive JANX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated May 2026)
- •Clinical data readouts for JANX007, JANX008, and JANX009 (throughout 2026)
- •Progress updates on JANX011 Phase 1 trial for autoimmune diseases
- •Achievement of preclinical milestones from Bristol Myers Squibb collaboration
Medium-Term (6-18 months)
- •Advancement of lead oncology programs (JANX007, 008, 009) into later-stage clinical trials
- •Expansion of Bristol Myers Squibb collaboration beyond initial scope
- •Potential new IND filings for additional TRACTr/TRACIr platform candidates
- •Initial data readouts for JANX011 in autoimmune diseases
Long-Term (18+ months)
- •Commercialization of a first-in-class T-cell engager for solid tumors
- •Establishment of the TRACTr platform as a dominant technology in oncology/autoimmune space
- •Multiple successful drug approvals leveraging proprietary platforms
- •Significant market share capture in next-generation oncology therapeutics
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for JANX?
- ✓
Positive Phase 1/2 clinical data readouts for JANX007, JANX008, JANX009, or JANX011
- ✓
Expansion of the Bristol Myers Squibb collaboration or new strategic partnerships
- ✓
Increased analyst price targets or upgrades based on pipeline progress
- ✓
Any indications of significant share dilution or unsustainable cash burn
Bull Case Analysis
See what could go right with Premium
Competing with JANX
See how Janux Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Janux Therapeutics Inc JANX | $855.3M | 8.3 | -7.7 | $10.0M | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Janux Therapeutics Inc (JANX)?
As of March 24, 2026, Janux Therapeutics Inc has a DVR Score of 8.3 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Janux Therapeutics Inc?
Janux Therapeutics Inc's market capitalization is approximately $855.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Janux Therapeutics Inc use?
JANX is the ticker symbol for Janux Therapeutics Inc. The company trades on the NGM.
What is the risk level for JANX stock?
Our analysis rates Janux Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of JANX?
Janux Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -7.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Janux Therapeutics Inc's revenue growing?
Janux Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is JANX stock profitable?
Janux Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the JANX DVR analysis updated?
Our AI-powered analysis of Janux Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for JANX (Janux Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.